ELAN Stock Recent News

Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.

I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive outlook for future growth.

Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.3 per share a year ago.

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter  2025 Financial Results: Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growth Reported Net Income of $11 million, Adjusted Net Income of $131 million Adjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2%  Reported EPS of $0.02, Adjusted EPS of $0.26 Net leverage ratio of 4.0x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024 Raising 2025 innovation revenue target by $60 million to $720 to $800 million Reported Net Loss of $(38) to $(14) million, raising guidance for Adjusted EBITDA to $850 to $890 million Reported Loss Per Share of $(0.08) to $(0.03), raising guidance for Adjusted EPS to $0.85 to $0.91  Outlook incorporates current estimate for net tariff impact and dynamic landscape, more t

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Elanco Animal Health (ELAN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market before the end of Q3 2025 GREENFIELD, Ind. , July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?

GREENFIELD, Ind. , July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025.